A Picrorhiza kurroa derivative, picroliv, attenuates the development of dextran-sulfate-sodium-induced colitis in mice

Mediators of Inflammation

Volumn 2012, Issue , 2012, Pages

  Zhang, De Kui ^a   Yu, Jian Jie ^a   Li, Yu Min ^b   Wei, Li Na ^a   Yu, Yi ^a   Feng, Yan Hu ^a   Wang, Xiang ^a  

^a LANZHOU UNIVERSITY   (China)

^b Key Laboratory of Digestive System Tumors   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; DEXTRAN SULFATE; INTERLEUKIN 1BETA; KUTKIN; MYELOPEROXIDASE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; CINNAMIC ACID DERIVATIVE; GLYCOSIDE; VANILLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON INJURY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; ULCERATIVE COLITIS; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; COLITIS; COLON; DRUG EFFECT; PATHOLOGY; PICRORHIZA KURROA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

MUS; PICRORHIZA KURROOA;

ANIMALS; CINNAMATES; COLITIS; COLON; DEXTRAN SULFATE; FEMALE; GLYCOSIDES; MICE; MICE, INBRED BALB C; PICRORHIZA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VANILLIC ACID;

EID: 84869077662     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2012/751629     Document Type: Article

References (64)

1. Fiocchi C., Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998 115 1 182 205 2-s2.0-0031781603 10.1016/S0016-5085(98) 70381-6 (Pubitemid 28307304)
2. Podolsky D. K., Inflammatory bowel disease. New England Journal of Medicine 2002 347 6 417 429 2-s2.0-0037043658 10.1056/NEJMra020831 (Pubitemid 34851835)
3. Sands B. E., Therapy of inflammatory bowel disease. Gastroenterology 2000 118 2 S68 S82 2-s2.0-0033981670 (Pubitemid 30094436)
4. Sandborn W. J., Targan S. R., Biologic therapy of inflammatory bowel disease. Gastroenterology 2002 122 6 1592 1608 2-s2.0-0036093570 (Pubitemid 34533555)
5. Ardizzone S., Porro G. B., Biologic therapy for inflammatory bowel disease. Drugs 2005 65 16 2253 2286 2-s2.0-27644566447 10.2165/00003495- 200565160-00002 (Pubitemid 41571985)
6. Reddy J. G., Loftus E. V. Jr., Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterology Clinics of North America 2006 35 4 837 855 2-s2.0-33751334334 10.1016/j.gtc.2006.09.008 (Pubitemid 44802970)
7. Papadakis K. A., Targan S. R., Role of cytokines in the pathogenesis of inflammatory bowel disease. Annual Review of Medicine 2000 51 289 298 2-s2.0-0034005581 10.1146/annurev.med.51.1.289 (Pubitemid 30216038)
8. Rogler G., Andus T., Cytokines in inflammatory bowel disease. World Journal of Surgery 1998 22 4 382 389 2-s2.0-0031914778 10.1007/s002689900401 (Pubitemid 28113526)
9. Ogata H., Hibi T., Cytokine and anti-cytokine therapies for inflammatory bowel disease. Current Pharmaceutical Design 2003 9 14 1107 1113 2-s2.0-0037268936 10.2174/1381612033455035 (Pubitemid 36443211)
10. Nakamura K., Honda K., Mizutani T., Akiho H., Harada N., Novel strategies for the treatment of inflammatory bowel disease: selective inhibition of cytokines and adhesion molecules. World Journal of Gastroenterology 2006 12 29 4628 4635 2-s2.0-33747641679 (Pubitemid 44269718)
11. Xiang J. Y., Wu L. G., Huang X. L., Zhang M., Pen L., Ouyan Q., Gan H. T., Amelioration of murine dextran sulfate sodium-induced colitis by nuclear factor- κ b decoy oligonucleotides. American Journal of Surgery 2009 197 6 797 805 2-s2.0-66149083594 10.1016/j.amjsurg.2008.04.012
12. Najafzadeh M., Reynolds P. D., Baumgartner A., Jerwood D., Anderson D., Chaga mushroom extract inhibits oxidative DNA damage in lymphocytes of patients with inflammatory bowel disease. BioFactors 2007 31 3-4 191 200 2-s2.0-57349117095 (Pubitemid 352789887)
13. Roessner A., Kuester D., Malfertheiner P., Schneider-Stock R., Oxidative stress in ulcerative colitis-associated carcinogenesis. Pathology Research and Practice 2008 204 7 511 524 2-s2.0-46749095883 10.1016/j.prp.2008.04.011
14. Dost T., Ozkayran H., Gokalp F., Yenisey C., Birincioglu M., The effect of Hypericum perforatum (St. John's Wort) on experimental colitis in rat. Digestive Diseases and Sciences 2009 54 6 1214 1221 2-s2.0-67349246086 10.1007/s10620-008-0477-6
15. 2? European Journal of Gastroenterology and Hepatology 2008 20 6 555 560 2-s2.0-43449128404 10.1097/MEG.0b013e3282f45751 (Pubitemid 351667896)
16. Baldwin A. S. Jr., Series introduction: the transcription factor NF- κ B and human disease. Journal of Clinical Investigation 2001 107 3 6 (Pubitemid 32047404)
17. Jobin C., Balfour Sartor R., NF- κ B signaling proteins as therapeutic targets for inflammatory bowel diseases. Inflammatory Bowel Diseases 2000 6 3 206 213 2-s2.0-0034243239
18. Glasgow J. N., Wood T., Perez-Polo J. R., Identification and characterization of nuclear factor κ B binding sites in the murine bcl-x promoter. Journal of Neurochemistry 2000 75 4 1377 1389 2-s2.0-0033811795 10.1046/j.1471-4159.2000.0751377.x
19. Tak P. P., Firestein G. S., NF- κ B: a key role in inflammatory diseases. Journal of Clinical Investigation 2001 107 7 11
20. Ghosh S., May M. J., Kopp E. B., NF- κ B and rel proteins: evolutionarily conserved mediators of immune responses. Annual Review of Immunology 1998 16 225 260 2-s2.0-0031897632 10.1146/annurev.immunol.16.1.225 (Pubitemid 28183365)
21. Schreiber S., Nikolaus S., Hampe J., Activation of nuclear factor κ B inflammatory bowel disease. Gut 1998 42 4 477 484 2-s2.0-0031925362 (Pubitemid 28186562)
22. Rogler G., Brand K., Vogl D., Page S., Hofmeister R., Andus T., Knuechel R., Baeuerle P. A., Scholmerich J., Gross V., Nuclear factor κ B is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998 115 2 357 369 2-s2.0-0031595210 10.1016/S0016-5085(98) 70202-1 (Pubitemid 28363428)
23. Neurath M. F., Pettersson S., Meyer Zum Buschenfelde K. H., Strober W., Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF- κ B abrogates established experimental colitis in mice. Nature Medicine 1996 2 9 998 1004 2-s2.0-0029836444 10.1038/nm0996-998 (Pubitemid 26306838)
24. Neurath M. F., Pettersson S., Predominant role of NF- κ B p65 in the pathogenesis of chronic intestinal inflammation. Immunobiology 1997 198 13 91 98 2-s2.0-0031434763 (Pubitemid 28021385)
25. Mehrotra R., Rawat S., Kulshreshtha D. K., Patnaik G. K., Dhawan B. N., In vitro studies on the effect of certain natural products against hepatitis B virus. Indian Journal of Medical Research Section B 1990 92 133 138 2-s2.0-0024999304 (Pubitemid 20300397)
26. Baruah C. C., Gupta P. P., Nath A., Patnaik L. G. K., Dhawan B. N., Anti-allergic and anti-anaphylactic activity of picroliva standardised iridoid glycoside fraction of Picrorhiza kurroa. Pharmacological Research 1998 38 6 487 492 2-s2.0-0032438658 10.1006/phrs.1998.0397 (Pubitemid 29002271)
27. Rastogi R., Srivastava A. K., Srivastava M., Rastogi A. K., Hepatocurative effect of picroliv and silymarin against aflatoxin B1 induced hepatotoxicity in rats. Planta Medica 2000 66 8 709 713 2-s2.0-0034523655 10.1055/s-2000-9907 (Pubitemid 32038925)
28. Rastogi R., Srivastava A. K., Rastogi A. K., Long term effect of aflatoxin B1 on lipid peroxidation in rat liver and kidney: effect of picroliv and silymarin. Phytotherapy Research 2001 15 4 307 310 2-s2.0-0034960753 10.1002/ptr.722 (Pubitemid 32613098)
29. Rastogi R., Srivastava A. K., Rastogi A. K., Biochemical changes induced in liver and serum of aflatoxin B1-treated male Wistar rats: preventive effect of Picroliv. Pharmacology and Toxicology 2001 88 2 53 58 2-s2.0-0035134819 (Pubitemid 32147081)
30. Saraswat B., Visen P. K. S., Patnaik G. K., Dhawan B. N., Protective effect of picroliv, active constituent of Picrorhiza kurrooa, against oxytetracycline induced hepatic damage. Indian Journal of Experimental Biology 1997 35 12 1302 1305 2-s2.0-0031435481 (Pubitemid 28011599)
31. Santra A., Das S., Maity A., Rao S. B., Mazumder D. N. G., Prevention of carbon tetrachloride-induced hepatic injury in mice by Picrorhiza kurrooa. Indian Journal of Gastroenterology 1998 17 1 6 9 2-s2.0-0031892548 (Pubitemid 28069353)
32. Girish C., Pradhan S. C., Hepatoprotective activities of picroliv, curcumin, and ellagic acid compared to silymarin on carbon-tetrachloride-induced liver toxicity in mice. Journal of Pharmacology and Pharmacotherapeutics 2012 3 2 149 155
33. Girish C., Koner B. C., Jayanthi S., Ramachandra Rao K., Rajesh B., Pradhan S. C., Hepatoprotective activity of picroliv, curcumin and ellagic acid compared to silymarin on paracetamol induced liver toxicity in mice. Fundamental and Clinical Pharmacology 2009 23 6 735 745 2-s2.0-70449487255 10.1111/j.1472-8206.2009.00722.x
34. Rastogi R., Saksena S., Garg N. K., Kapoor N. K., Agarwal D. P., Dhawan B. N., Picroliv protects against alcohol-induced chronic hepatotoxicity in rats. Planta Medica 1996 62 3 283 285 2-s2.0-0030007038 10.1055/s-2006-957882 (Pubitemid 26201078)
35. Singh A. K., Mani H., Seth P., Gaddipati J. P., Kumari R., Banuadha K. K., Sharma S. C., Kulshreshtha D. K., Maheshwari R. K., Picroliv preconditioning protects the rat liver against ischemia-reperfusion injury. European Journal of Pharmacology 2000 395 3 229 239 2-s2.0-0034600236 10.1016/S0014-2999(00)00146-1 (Pubitemid 30254373)
36. Seth P., Kumari R., Madhavan S., Singh A. K., Mani H., Banaudha K. K., Sharma S. C., Kulshreshtha D. K., Maheshwari R. K., Prevention of renal ischemia-reperfusion-induced injury in rats by picroliv. Biochemical Pharmacology 2000 59 10 1315 1322 2-s2.0-0034657017 10.1016/S0006-2952(00)00268- 9 (Pubitemid 30157894)
37. Jia Q., Hong M. F., Minter D., Pikuroside: a novel iridoid from Picrorhiza kurroa. Journal of Natural Products 1999 62 6 901 903 2-s2.0-0032985471 10.1021/np980493+ (Pubitemid 29296335)
38. Sinha S., Mehrotra J., Bala L., Jaiswal A. K., Dhawan B. N., Picroliv, the iridoid glycoside fraction of Picrorhiza kurroa, selectively augments human T cell response to mycobacterial protein antigens. Immunopharmacology and Immunotoxicology 1998 20 4 579 588 2-s2.0-0031753841 (Pubitemid 28491716)
39. Shakya N., Sane S. A., Gupta S., Antileishmanial efficacy of fluconazole and miltefosine in combination with an immunomodulatorpicroliv. Parasitology Research 2011 108 4 793 800 2-s2.0-79956223246 10.1007/s00436-010-2230-2
40. Jeena K. J., Joy K. L., Kuttan R., Effect of Emblica officinalis, Phyllanthus amarus and Picrorrhiza kurroa on N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Letters 1999 136 1 11 16 2-s2.0-0033026704 10.1016/S0304-3835(98)00294-8 (Pubitemid 29142296)
41. Rajeshkumar N. V., Kuttan R., Inhibition of N-nitrosodiethylamineinduced hepatocarcinogenesis by Picroliv. Journal of Experimental and Clinical Cancer Research 2000 19 4 459 465 2-s2.0-0034465205
42. Rajeshkumar N. V., Kuttan R., Protective effect of Picroliv, the active constituent of Picrorhiza kurroa, against chemical carcinogenesis in mice. Teratogenesis Carcinogenesis and Mutagenesis 2001 21 4 303 313 2-s2.0-0034969426 10.1002/tcm.1018 (Pubitemid 32613819)
43. Rajeshkumar N. V., Kuttan R., Modulation of carcinogenic response and antioxidant enzymes of rats administered with 1,2-dimethylhydrazine by Picroliv. Cancer Letters 2003 191 2 137 143 2-s2.0-0037430537 10.1016/S0304-3835(02) 00203-3 (Pubitemid 36255598)
44. Chander R., Kapoor N. K., Dhawan B. N., Picroliv, picroside-I and kutkoside from Picrorhiza kurrooa are scavengers of superoxide anions. Biochemical Pharmacology 1992 44 1 180 183 2-s2.0-0026634040 10.1016/0006-2952(92)90054-M
45. Seth P., Sundar S. V., Seth R. K., Sidhu G. S., Sharma S. C., Kulshreshtha D. K., Maheshwari R. K., Picroliv modulates antioxidant status and down-regulates AP1 transcription factor after hemorrhage and resuscitation. Shock 2003 19 2 169 175 2-s2.0-0041308096
46. Gaddipati J. P., Madhavan S., Sidhu G. S., Singh A. K., Seth P., Maheshwari R. K., Picroliva natural product protects cells and regulates the gene expression during hypoxia/reoxygenation. Molecular and Cellular Biochemistry 1999 194 1-2 271 281 2-s2.0-0033024460 10.1023/A:1006982028460 (Pubitemid 29245569)
47. Anand P., Kunnumakkara A. B., Harikumar K. B., Kwang S. A., Badmaev V., Aggarwal B. B., Modification of cysteine residue in p65 subunit of nuclear factor- κ B (NF- κ B) by picroliv suppresses NF- κ B-regulated gene products and potentiates apoptosis. Cancer Research 2008 68 21 8861 8870 2-s2.0-55349112154 10.1158/0008-5472.CAN-08-1902
48. Mittal N., Gupta N., Saksena S., Goyal N., Roy U., Rastogi A. K., Protective effect of Picroliv from Picrorhiza kurroa against Leishmania donovani infections in Mesocricetus auratus. Life Sciences 1998 63 20 1823 1834 2-s2.0-0032500866 10.1016/S0024-3205(98)00456-1 (Pubitemid 28511615)
49. Murthy S. N. S., Cooper H. S., Shim H., Shah R. S., Ibrahim S. A., Sedergran D. J., Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Digestive Diseases and Sciences 1993 38 9 1722 1734 2-s2.0-0027275654 (Pubitemid 23271431)
50. Ten Hove T., Van den Blink B., Pronk I., Drillenburg P., Peppelenbosch M. P., Van Deventer S. J. H., Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis. Gut 2002 50 4 507 512 2-s2.0-0036278884 10.1136/gut.50.4.507 (Pubitemid 34638870)
51. Martín A. R., Villegas I., Sánchez-Hidalgo M., De La Lastra C. A., The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. British Journal of Pharmacology 2006 147 8 873 885 2-s2.0-33646572516 10.1038/sj.bjp.0706469
52. Kurtovic J., Segal I., Recent advances in biological therapy for inflammatory bowel disease. Tropical Gastroenterology 2004 25 1 9 14 2-s2.0-4344702394
53. Thukral C., Cheifetz A., Peppercorn M. A., Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date. Drugs 2006 66 16 2059 2065 2-s2.0-33847709966 10.2165/00003495-200666160-00002 (Pubitemid 46372357)
54. Aberra F. N., Lichtenstein G. R., Infliximab in ulcerative colitis. Gastroenterology Clinics of North America 2006 35 4 821 836 2-s2.0-33751213060 10.1016/j.gtc.2006.09.002 (Pubitemid 44791836)
55. Feagan B. G., Reinisch W., Rutgeerts P., Sandborn W. J., Yan S., Eisenberg D., Bala M., Johanns J., Olson A., Hanauer S. B., The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. American Journal of Gastroenterology 2007 102 4 794 802 2-s2.0-33947709456 10.1111/j.1572-0241.2007.01094.x (Pubitemid 46496629)
56. Zhang D. K., Cheng L. N., Huang X. L., Shi W., Xiang J. Y., Gan H. T., Tetrandrine ameliorates dextran-sulfate-sodium-induced colitis in mice through inhibition of nuclear factor- κ B activation. International Journal of Colorectal Disease 2009 24 1 5 12 2-s2.0-57049165969 10.1007/s00384-008-0544-7
57. Ishihara T., Tanaka K. I., Tasaka Y., Namba T., Suzuki J., Ishihara T., Okamoto S., Hibi T., Takenaga M., Igarashi R., Sato K., Mizushima Y., Mizushima T., Therapeutic effect of lecithinized superoxide dismutase against colitis. Journal of Pharmacology and Experimental Therapeutics 2009 328 1 152 164 2-s2.0-59149097248 10.1124/jpet.108.144451
58. Zhou Y. H., Yu J. P., Liu Y. F., Teng X. J., Ming M., Lv P., An P., Liu S. Q., Yu H. G., Effects of Ginkgo biloba extract on inflammatory mediators (SOD, MDA, TNF- α NF- κ Bp65, IL-6) in TNBS-induced colitis in rats. Mediators of Inflammation 2006 2006 9 2-s2.0-33749508679 10.1155/MI/2006/92642 92642 (Pubitemid 44526079)
59. Liu X. C., Mei Q., Xu J. M., Hu J., Balsalazine decreases intestinal mucosal permeability of dextran sulfate sodium-induced colitis in mice. Acta Pharmacologica Sinica 2009 30 7 987 993 2-s2.0-67651171407 10.1038/aps.2009.77
60. Kurutas E. B., Cetinkaya A., Bulbuloglu E., Kantarceken B., Effects of antioxidant therapy on leukocyte myeloperoxidase and Cu/Zn-superoxide dismutase and plasma malondialdehyde levels in experimental colitis. Mediators of Inflammation 2005 2005 6 390 394 2-s2.0-29144454969 10.1155/MI.2005.390 (Pubitemid 41803409)
61. Liu L. N., Mei Q. B., Liu L., Zhang F., Liu Z. G., Wang Z. P., Wang R. T., Protective effects of Rheum tanguticum polysaccharide against hydrogen peroxide-induced intestinal epithelial cell injury. World Journal of Gastroenterology 2005 11 10 1503 1507 2-s2.0-16344365084 (Pubitemid 40468086)
62. Fridovich I., Pryor W. A., Oxygen radicals, hydrogen peroxide,and oxygen toxicity. Free Radicals in Biology 1976 New York, NY, USA Academic Press 239 277
63. Suzuki Y., Matsumoto T., Okamoto S., Hibi T., A lecithinized superoxide dismutase (PC-SOD) improves ulcerative colitis. Colorectal Disease 2008 10 9 931 934 2-s2.0-54949090399 10.1111/j.1463-1318.2008.01487.x
64. Uchimura K., Nagasaka A., Hayashi R., Makino M., Nagata M., Kakizawa H., Kobayashi T., Fujiwara K., Kato T., Iwase K., Shinohara R., Kato K., Itoh M., Changes in superoxide dismutase activities and concentrations and myeloperoxidase activities in leukocytes from patients with diabetes mellitus. Journal of Diabetes and its Complications 1999 13 5-6 264 270 2-s2.0-0033549921 10.1016/S1056-8727(99)00053-7 (Pubitemid 30182606)